Risk adjusted net present value: What is the current valuation of I-Mab’s Lemzoparlimab?
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Solid Tumor.
Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Solid Tumor.
What's Your Reaction?
